FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2526-2527 June 5, 2008 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

By Stewart Justman. 236 pp. Chicago, Ivan R. Dee, 2008. $26. ISBN 978-1-56663-627-8.

In 2003, the Journal published an article on the influence of finasteride in the prevention of prostate cancer. This study demonstrated that men who took the drug experienced a 24.8% lower risk of prostate cancer, as compared with men who received a placebo, but had a higher risk of high-grade disease. This startling finding raised an ethical dilemma about the risk–benefit ratio and the question of whether any risk was too high. Stewart Justman is well credentialed to attack this thorny question. He is a noted author, a professor of liberal studies at the University of Montana, a lay member . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.